Cancer Immunology, Immunotherapy

, Volume 60, Issue 8, pp 1153–1160

Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

  • Arcadi Cipponi
  • Grégoire Wieers
  • Nicolas van Baren
  • Pierre G. Coulie
Focussed Research Review

DOI: 10.1007/s00262-011-1026-2

Cite this article as:
Cipponi, A., Wieers, G., van Baren, N. et al. Cancer Immunol Immunother (2011) 60: 1153. doi:10.1007/s00262-011-1026-2

Abstract

Tumor-infiltrating T lymphocytes (TILs) are observed in a number of human primary or metastatic tumors. Recently, gene expression profiling experiments suggested that the presence of T cells in metastatic melanomas before vaccinating the patients with tumor antigens could be a biomarker for clinical benefit from the vaccines. In this context, we review results pertaining to TILs in human melanomas, their prognostic value, and some possible reasons why their presence could help in selecting melanoma patients for vaccination against tumor-specific antigens.

Keywords

MelanomaT lymphocyteImmunotherapyPrognosisPIVAC 10

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Arcadi Cipponi
    • 1
  • Grégoire Wieers
    • 1
    • 2
  • Nicolas van Baren
    • 1
    • 2
  • Pierre G. Coulie
    • 1
  1. 1.de Duve InstituteUniversité catholique de LouvainBrusselsBelgium
  2. 2.Ludwig Institute for Cancer Research, Brussels BranchBrusselsBelgium